|

Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

RECRUITINGSponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Actively Recruiting
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Started2025-07
Est. completion2026-09
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07059936

Summary

CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026;
2. Aged \> 18 years old;
3. At least one CT scan or MR scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than liver cancer;
4. Unclear pathological diagnosis.

Conditions4

CancerHepatocellular Carcinoma (HCC)Liver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.